Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights
Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly
Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly